growing patent portfolio which includes one issued broad-based US patent, a notice of allowance on a second U.S. patent, and more than 40 Pending the US and foreign patent applications and provisional filings, including the composition of matter applications for its proprietary formulations. The company has completed in-vivo proof of concept in an animal model for presbyopia and has begun development activities leading to clinical studies in man.

It was established in 2000 and is headquartered in Fort Worth, Texas.